ArticleThe Journal of biological chemistry2026
Temporal transcriptomic profiling uncovers multilevel suppression of RANKL-driven osteoclast differentiation by 14-3-3ζ.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Receptor activator of nuclear factor κB ligand (RANKL) is the central driver of osteoclast differentiation and function, yet the regulatory checkpoints that restrain RANKL signaling remain incompletely defined. We previously demonstrated that 14-3-3ζ (Ywhaz) suppresses RANKL signaling by targeting TRAF6 at the post-translational level. Here, we identify a previously unrecognized transcriptional mechanism by which 14-3-3ζ constrains RANKL-induced osteoclastogenesis. Using an unbiased, time-resolved transcriptomic analysis (0-40 h) in primary rat bone marrow-derived preosteoclasts, we show that loss of 14-3-3ζ augments RANKL-induced expression of canonical osteoclast genes (Acp5, Ctsk, Car2), confirming its suppressive role in osteoclast differentiation. Beyond core osteoclast markers, 14-3-3ζ deficiency enhanced the induction of chemokines (Ccl7), focal adhesion (Rac2), and lysosomal markers (Lamp1, CTSZ), identifying its role in regulating the amplification of RANKL signaling. Mechanistically, we observed that 14-3-3ζ targets both positive and negative regulators of RANKL. While 14-3-3ζ promoted Lgr4, an inhibitor of RANKL signaling and NFATc1 expression, it concurrently suppressed SHP-2 (Ptpn11) expression, a phosphatase that promotes cell-cell fusion, a critical late step in osteoclast formation. Inhibition of SHP-2 activity with a specific pharmacological inhibitor abolished osteoclast differentiation in 14-3-3ζ-deficient cells, establishing SHP-2 as a functional effector downstream of 14-3-3ζ. Collectively, these findings reveal that 14-3-3ζ exerts dual transcriptional control over RANKL signaling, limiting both early osteoclastogenic gene induction and late-stage cell fusion. Loss of this regulatory brake increases susceptibility to RANKL-induced osteoclastogenesis, providing a mechanistic basis for enhanced bone loss, and highlighting 14-3-3ζ as a potential therapeutic target in inflammatory bone disorders.
Indexed as
Identifiers
42637076What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.